Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05743621 · ClinicalTrials.gov registry record · Phase 1

Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer

A Phase 1 study of Prostatic Neoplasms, Castration-Resistant, sponsored by Weill Medical College of Cornell University.

Recruiting
Registry status
Phase 1
Development phase
30
Enrollment target
1
Study location

NCT05743621 is a Phase 1 study of Prostatic Neoplasms, Castration-Resistant that is actively recruiting participants, run by Weill Medical College of Cornell University. The registered enrollment target is 30 participants, below the 738-participant average among 10 other Prostatic Neoplasms, Castration-Resistant trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05743621, a Phase 1 study of Prostatic Neoplasms, Castration-Resistant, is actively recruiting participants, sponsored by Weill Medical College of Cornell University.

RECRUITING
Registry status
Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine what effects (good and bad) Enzalutamide and TVB-2640 have in the treatment of prostate cancer whose prostate cancer has spread to other parts of their body and that has not gotten better with previous treatment. This study is a Phase I clinical trial. Phase I clinical trials test the side effects of an investigational drug or an investigational combination with another drug. "Investigational" means that the drug is still being studied and research doctors are trying to find out more about it. Although Enzalutamide is already being used to treat men with prostate cancer, combining Enzalutamide with TVB-2640 together in patients with prostate cancer is considered experimental. This research study is being done because additional effective treatments are needed for prostate cancer that has spread and is growing despite hormone suppression. By doing this study, the investigators hope to learn if combining Enzalutamide with TVB-2640 can be done safely. Participation in this research will last about 12 to 24 months after enrollment.

Conditions Studied

Prostatic Neoplasms, Castration-Resistant

Interventions

  • DRUG Enzalutamide
  • DRUG TVB-2640

Study Locations (1)

New York

  • Weill Cornell Medicine/NewYork-Presbyterian Hospital - New York

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2023-11-20
Est. Completion 2029-01-25
Phase Phase 1

Sponsor

Weill Medical College of Cornell University

701 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05743621

The ClinicalTrials.gov registry entry for NCT05743621 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 738-participant average among 10 other Prostatic Neoplasms, Castration-Resistant trials with a reported enrollment target (96% lower). The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostatic Neoplasms, Castration-Resistant appearing as the primary indexed condition, and to 2 interventions - of which Enzalutamide is the first listed.

NCT05743621 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT05743621 about?

NCT05743621 is a clinical study titled "Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer". The purpose of this study is to determine what effects (good and bad) Enzalutamide and TVB-2640 have in the treatment of prostate cancer whose prostate cancer has spread to other parts of their body and that has not gotten better with previous treatment. This study is a Phase I clinical trial. Phase...

What is the current status of trial NCT05743621?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2023-11-20. Estimated completion is 2029-01-25.

What conditions does trial NCT05743621 study?

This clinical trial studies the following conditions: Prostatic Neoplasms, Castration-Resistant.

What interventions are being tested in trial NCT05743621?

The interventions under investigation include: Enzalutamide (DRUG), TVB-2640 (DRUG).

Who is sponsoring clinical trial NCT05743621?

This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05743621 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostatic Neoplasms, Castration-Resistant

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostatic Neoplasms, Castration-Resistant

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.